COLUMN GROUP L P
CIK 1347769 · last filed 2023-11-17
COLUMN GROUP L P is a corporate insider who has filed 21 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing shows the insider bought $155.1K of NGM on Nov 17, 2023. Across all open-market trades the lifetime net is +$67.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $39.1M across reported positions. The firm reports its address in San Francisco, CA. 77 SEC filings were submitted jointly with COLUMN GROUP GP, LP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NGM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 12,053,195 | $1.54 | $18.56M | $67.18M | 19 | 2023-11-17 |
| NRIX | 10%+ Owner | 1,533,716 | $25.51 | $39.13M | $0 | 1 | 2021-05-07 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 2,607,060 | $33.99 | $88.61M | $0 | 1 | 2020-12-16 |
Recent Filings
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-17 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +226,310 | $155.1K | EDGAR |
| 2023-02-01 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +368,544 | $1.84M | EDGAR |
| 2023-01-25 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +19,800 | $99.0K | EDGAR |
| 2023-01-23 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +381,390 | $1.91M | EDGAR |
| 2023-01-23 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +76,278 | $381.2K | EDGAR |
| 2022-11-07 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +1,391,480 | $6.84M | EDGAR |
| 2022-11-07 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +278,296 | $1.37M | EDGAR |
| 2022-10-31 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +153,754 | $747.3K | EDGAR |
| 2022-10-27 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +247,640 | $1.19M | EDGAR |
| 2022-06-06 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +273,600 | $3.57M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.